LAS VEGAS and HAMILTON, N.J., July 11, 2012 /PRNewswire/ -- Cleveland Clinic Lou Ruvo Center for Brain Health and MedAvante, Inc. announced a collaborative alliance using MedAvante's centralized clinical trial services to optimize testing of treatments for Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and other neurodegenerative disorders.
Dr. Jeffrey Cummings, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health and one of the world's leading Alzheimer's disease researchers, said the combination of capabilities will advance signal detection in neurocognition.
"Measuring relatively small changes in cognitive performance over prolonged periods of time is an extremely difficult challenge," Dr. Cummings said. "Standardizing research assessments will help us to produce higher quality research data with less error, which ultimately will translate into more advanced treatments for patients."
Cleveland Clinic Lou Ruvo Center for Brain Health, which specializes in care of patients with neurocognitive deficits and developing new therapies, will implement MedAvante central trial services for controlling subject selection and endpoint data collection.
MedAvante central trial services are designed to achieve consistent and uniformly high assessment data quality across sites and studies. The alliance provides for additional collaboration by MedAvante's senior scientists with Dr. Cummings to study the impact of signal detection processes on outcome data.
"This agreement emphasizes the value of scientifically rigorous methodologies MedAvante has developed and implemented for various clinical trials in AD and MCI as well as psychiatric disorders such as depression and schizophrenia," said Paul M. Gilbert, co-founder and Chief Executive Officer of MedAvante.
"MedAvante has scientific and operational capabilities in place to enhance signal detection," Gilbert said. "Joining forc
|SOURCE MedAvante, Inc.|
Copyright©2012 PR Newswire.
All rights reserved